Is There a Role for Autotransplants in AML in First Remission?

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 17-20

  Seshadri, Tara ^a   Keating, Armand ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

AML; Autotransplants; First remission

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTARABINE; IDARUBICIN; PLERIXAFOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PROGNOSIS; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

EID: 64749105149     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.11.016     Document Type: Article

References (21)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335 (1996) 91-97
2. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
3. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359 (2002) 2065-2071
4. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
5. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105 (2005) 2677-2684
6. Ferrara F., Palmieri S., and Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 66 (2008) 181-193
7. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96 (2000) 4075-4083
8. Zittoun R.A., Mandelli F., Willemze R., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332 (1995) 217-223
9. Harousseau J.L., Cahn J.Y., Pignon B., et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 90 (1997) 2978-2986
10. Breems D.A., Boogaerts M.A., Dekker A.W., et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 128 (2005) 59-65
11. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 (1998) 1649-1656
12. Burnett A.K., Goldstone A.H., Stevens R.M., et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukemia Working Parties. Lancet 351 (1998) 700-708
13. Schlenk R.F., Benner A., Krauter J., et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22 (2004) 3741-3750
14. Delaunay J., Vey N., Leblanc T., et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 102 (2003) 462-469
15. Tsimberidou A.M., Stavroyianni N., Viniou N., et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 97 (2003) 1721-1731
16. Buchner T., Berdel W.E., Schoch C., et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24 (2006) 2480-2489
17. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102 (2003) 1232-1240
18. Cornelissen J.J., van Putten W.L.J., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 109 (2007) 3658-3666
19. Keating A., Kukreja M., Silva G., et al. Similar 5-year survival after peripheral blood autotransplants versus HLA sibling myeloablative transplants for acute myeloid leukemia in first complete remission. ASH Abstract. Blood (2008)
20. Schlenk R.F., Döhner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358 (2008) 1909-1918
21. Calandra G., McCarty J., McGuirk J., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and//or cytokine treatment: compassionate use data. Bone Marrow Transplant 41 (2007) 331-338